Tech Company Financing Transactions
Navinci Diagnostics Funding Round
On 7/12/2022, Navinci Diagnostics raised $8.5 million in Series A investment from Segulah Medical Acceleration, Beijer Ventures and Landegren Gene Technology.
Transaction Overview
Company Name
Announced On
7/12/2022
Transaction Type
Venture Equity
Amount
$8,540,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate international commercialization and partner with pharma companies, as well as companies with complementary technologies, to offer complete solutions for its customers.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
Care of Uppsala University BMC D11 Plan 1, Husargatan 3
Uppsala, 75124
Sweden
Uppsala, 75124
Sweden
Phone
Website
Email Address
Overview
Navinci (formerly Olink Bioscience), has a proud history of inventing analytic technologies for nucleic acids and proteins, identifying commercial opportunities and bringing successful products to the market to serve scientists in research and drug development. First founded in 2004 on the breakthrough innovations by Professor Ulf Landegren and colleagues at Uppsala University, the company has directly marketed a wide range of products including the Duolink in situ protein detection product line, which was acquired by Sigma-Aldrich in 2016, and Proseek multiplex panels, now known as Olink Target and marketed by Olink Proteomics.
Management Team
Browse more venture capital transactions:
Prev: 7/12/2022: Micropep venture capital transaction
Next: 7/12/2022: Tecton.ai venture capital transaction
Share this article
About Our VC Transactions Data
We report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs